These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 17546767)

  • 21. Successful pregnancy outcome in a patient with Fabry disease receiving enzyme replacement therapy with agalsidase alfa.
    Wendt S; Whybra C; Kampmann C; Teichmann E; Beck M
    J Inherit Metab Dis; 2005; 28(5):787-8. PubMed ID: 16151910
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enzyme replacement therapy of Fabry disease.
    Clarke JT; Iwanochko RM
    Mol Neurobiol; 2005 Aug; 32(1):43-50. PubMed ID: 16077182
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry Registry.
    Ortiz A; Abiose A; Bichet DG; Cabrera G; Charrow J; Germain DP; Hopkin RJ; Jovanovic A; Linhart A; Maruti SS; Mauer M; Oliveira JP; Patel MR; Politei J; Waldek S; Wanner C; Yoo HW; Warnock DG
    J Med Genet; 2016 Jul; 53(7):495-502. PubMed ID: 26993266
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Kidney function and 24-hour proteinuria in patients with Fabry disease during 36 months of agalsidase alfa enzyme replacement therapy: a Brazilian experience.
    Thofehrn S; Netto C; Cecchin C; Burin M; Matte U; Brustolin S; Nunes AC; Coelho J; Tsao M; Jardim L; Giugliani R; Barros EJ
    Ren Fail; 2009; 31(9):773-8. PubMed ID: 19925283
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enzyme replacement therapy in Fabry disease: comparison of agalsidase alfa and agalsidase beta.
    Mehta A; Beck M; Kampmann C; Frustaci A; Germain DP; Pastores GM; Sunder-Plassmann G
    Mol Genet Metab; 2008; 95(1-2):114-5. PubMed ID: 18701330
    [No Abstract]   [Full Text] [Related]  

  • 26. Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation.
    Warnock DG; Ortiz A; Mauer M; Linthorst GE; Oliveira JP; Serra AL; Maródi L; Mignani R; Vujkovac B; Beitner-Johnson D; Lemay R; Cole JA; Svarstad E; Waldek S; Germain DP; Wanner C;
    Nephrol Dial Transplant; 2012 Mar; 27(3):1042-9. PubMed ID: 21804088
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of enzyme replacement therapy in Fabry disease.
    Barbey F; Hayoz D; Widmer U; Burnier M
    Curr Med Chem Cardiovasc Hematol Agents; 2004 Oct; 2(4):277-86. PubMed ID: 15320778
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enzyme replacement therapy for Fabry disease, an inherited nephropathy.
    Desnick RJ; Banikazemi M; Wasserstein M
    Clin Nephrol; 2002 Jan; 57(1):1-8. PubMed ID: 11837797
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enzyme replacement therapy with agalsidase beta in kidney transplant patients with Fabry disease: a pilot study.
    Mignani R; Panichi V; Giudicissi A; Taccola D; Boscaro F; Feletti C; Moneti G; Cagnoli L
    Kidney Int; 2004 Apr; 65(4):1381-5. PubMed ID: 15086478
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Development of an orphan drug to treat a genetic disease: the paradigm of agalsidase beta].
    Germain DP; Benistan K
    Presse Med; 2007 Mar; 36 Spec No 1():1S69-75. PubMed ID: 17546772
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enzyme replacement therapy and Fabry kidney disease: quo vadis?
    Warnock DG
    J Am Soc Nephrol; 2007 May; 18(5):1368-70. PubMed ID: 17429046
    [No Abstract]   [Full Text] [Related]  

  • 32. Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy.
    Banikazemi M; Ullman T; Desnick RJ
    Mol Genet Metab; 2005 Aug; 85(4):255-9. PubMed ID: 15939645
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Uneventful pregnancy outcome after enzyme replacement therapy with agalsidase beta in a heterozygous female with Fabry disease: A case report.
    Germain DP; Bruneval P; Tran TC; Balouet P; Richalet B; Benistan K
    Eur J Med Genet; 2010; 53(2):111-2. PubMed ID: 20045092
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Foot process effacement is an early marker of nephropathy in young classic Fabry patients without albuminuria.
    Tøndel C; Kanai T; Larsen KK; Ito S; Politei JM; Warnock DG; Svarstad E
    Nephron; 2015; 129(1):16-21. PubMed ID: 25531941
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiac involvement in Fabry's disease.
    Nicholls K
    Heart Lung Circ; 2005; 14 Suppl 2():S18-20. PubMed ID: 16352280
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of agalsidase alfa replacement therapy on Fabry disease-related hypertrophic cardiomyopathy: a 12- to 36-month, retrospective, blinded echocardiographic pooled analysis.
    Kampmann C; Linhart A; Devereux RB; Schiffmann R
    Clin Ther; 2009 Sep; 31(9):1966-76. PubMed ID: 19843486
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Neurological manifestations of Fabry disease].
    Mendióroz M; Fernández-Cadenas I; Montaner J
    Rev Neurol; 2006 Dec 16-31; 43(12):739-45. PubMed ID: 17160925
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nephropathy in Fabry disease: the importance of early diagnosis and testing in high-risk populations.
    Oqvist B; Brenner BM; Oliveira JP; Ortiz A; Schaefer R; Svarstad E; Wanner C; Zhang K; Warnock DG
    Nephrol Dial Transplant; 2009 Jun; 24(6):1736-43. PubMed ID: 19293136
    [No Abstract]   [Full Text] [Related]  

  • 39. Fabry disease: overall effects of agalsidase alfa treatment.
    Beck M; Ricci R; Widmer U; Dehout F; de Lorenzo AG; Kampmann C; Linhart A; Sunder-Plassmann G; Houge G; Ramaswami U; Gal A; Mehta A
    Eur J Clin Invest; 2004 Dec; 34(12):838-44. PubMed ID: 15606727
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Functional renal investigation in Fabry disease].
    Froissart M; Benistan K; Germain DP
    Presse Med; 2007 Mar; 36 Spec No 1():1S36-42. PubMed ID: 17546766
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.